Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

McGuirk

Showing results (471-480 of 583) with videos related to

Pageof 59
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2023
Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 StudyJurjen Versluis, Wael Saber, Harrison K Tsai, et al.
Cytotherapy|December 9, 2003
Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind studyS S Joshi, M R Bishop, J C Lynch, et al.
JCO Oncology Practice|January 23, 2024
Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102Wael Saber, Aasthaa Bansal, Lily Li, et al.
Blood Advances|July 23, 2024
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucelNausheen Ahmed, William Wesson, Forat Lutfi, et al.
Blood Advances|November 10, 2022
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapyKitsada Wudhikarn, Ana Alarcon Tomas, Jessica R Flynn, et al.
Blood Advances|June 24, 2026
Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium AnalysisKitsada Wudhikarn, Maria Bromberg, Jamie Brower, et al.
Oncogene|May 9, 2017
Identification of a TLR2-regulated gene signature associated with tumor cell growth in gastric cancerA C West, K Tang, H Tye, et al.
Transplantation and Cellular Therapy|July 20, 2021
Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-AnalysisMoazzam Shahzad, Raheel S Siddiqui, Iqra Anwar, et al.
Blood Advances|December 12, 2022
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndromeShakthi T Bhaskar, Vivek G Patel, David L Porter, et al.
Chemical Science|June 25, 2026
Increasing connectivity through self-complementarity enables permanent porosity in a halogen-bonded organic frameworkMichael P Moghadasnia, Hayden A Evans, Adria S Hippely, et al.
Pageof 59

Showing results (471-480 of 583) with videos related to

Sort By:
Pageof 59
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2023
Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 StudyJurjen Versluis, Wael Saber, Harrison K Tsai, et al.
Cytotherapy|December 9, 2003
Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind studyS S Joshi, M R Bishop, J C Lynch, et al.
JCO Oncology Practice|January 23, 2024
Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102Wael Saber, Aasthaa Bansal, Lily Li, et al.
Blood Advances|July 23, 2024
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucelNausheen Ahmed, William Wesson, Forat Lutfi, et al.
Blood Advances|November 10, 2022
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapyKitsada Wudhikarn, Ana Alarcon Tomas, Jessica R Flynn, et al.
Blood Advances|June 24, 2026
Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium AnalysisKitsada Wudhikarn, Maria Bromberg, Jamie Brower, et al.
Oncogene|May 9, 2017
Identification of a TLR2-regulated gene signature associated with tumor cell growth in gastric cancerA C West, K Tang, H Tye, et al.
Transplantation and Cellular Therapy|July 20, 2021
Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-AnalysisMoazzam Shahzad, Raheel S Siddiqui, Iqra Anwar, et al.
Blood Advances|December 12, 2022
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndromeShakthi T Bhaskar, Vivek G Patel, David L Porter, et al.
Chemical Science|June 25, 2026
Increasing connectivity through self-complementarity enables permanent porosity in a halogen-bonded organic frameworkMichael P Moghadasnia, Hayden A Evans, Adria S Hippely, et al.
Pageof 59